These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38365541)

  • 1. Omission of Breast Surgery in Exceptional Responders.
    Tasoulis MK; Lee HB; Kuerer HM
    Clin Breast Cancer; 2024 Jun; 24(4):310-318. PubMed ID: 38365541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omission of breast surgery in selected breast cancer patients with excellent response to neoadjuvant systemic therapy.
    Tasoulis MK; Muktar S; Smith I; Roche N; MacNeill F
    Eur J Surg Oncol; 2024 Jun; 50(6):108277. PubMed ID: 38522333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery.
    Pfob A; Sidey-Gibbons C; Rauch G; Thomas B; Schaefgen B; Kuemmel S; Reimer T; Hahn M; Thill M; Blohmer JU; Hackmann J; Malter W; Bekes I; Friedrichs K; Wojcinski S; Joos S; Paepke S; Degenhardt T; Rom J; Rody A; van Mackelenbergh M; Banys-Paluchowski M; Große R; Reinisch M; Karsten M; Golatta M; Heil J
    J Clin Oncol; 2022 Jun; 40(17):1903-1915. PubMed ID: 35108029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can axillary surgery be omitted in patients with breast pathologic complete response after neoadjuvant systemic therapy for breast cancer? A real-world retrospective study in China.
    Chen R; Li S; Li Y; Zhu Q; Shi X; Xu L; Xu Y; Zhang W; Huang X; Wang J; Zha X
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3495-3501. PubMed ID: 34398298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multidisciplinary team and patient perspective on omission of surgery after neoadjuvant systemic therapy for early breast cancer: A European Society of Surgical Oncology (ESSO) Research Academy survey.
    Caballero C; Lundon DJ; Vasileva-Slaveva M; Montagna G; Bonci EA; Brandl A; Smith H; Kok JHH; Holmberg CJ; Sayyed R; Santrac N; Suppan I; Kaul P; Vassos N; Lorenzon L; Murphy M; Ceelen W; de Azambuja E; McIntosh SA; Rubio IT
    Eur J Surg Oncol; 2024 Oct; 50(10):108585. PubMed ID: 39146663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials.
    van la Parra RF; Kuerer HM
    Breast Cancer Res; 2016 Mar; 18(1):28. PubMed ID: 26951131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying pathologic complete response of the breast after neoadjuvant systemic therapy with ultrasound guided biopsy to eventually omit surgery: Study design and feasibility of the MICRA trial (Minimally Invasive Complete Response Assessment).
    van der Noordaa MEM; van Duijnhoven FH; Loo CE; van Werkhoven E; van de Vijver KK; Wiersma T; Winter-Warnars HAO; Sonke GS; Vrancken Peeters MTFD
    Breast; 2018 Aug; 40():76-81. PubMed ID: 29698928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innovative Standards in Surgery of the Breast after Neoadjuvant Systemic Therapy.
    Hadar T; Koretz M; Nawass M; Allweis TM
    Breast Care (Basel); 2021 Dec; 16(6):590-597. PubMed ID: 35087362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy.
    Kuerer HM; Rauch GM; Krishnamurthy S; Adrada BE; Caudle AS; DeSnyder SM; Black DM; Santiago L; Hobbs BP; Lucci A; Gilcrease M; Hwang RF; Candelaria RP; Chavez-MacGregor M; Smith BD; Arribas E; Moseley T; Teshome M; Miggins MV; Valero V; Hunt KK; Yang WT
    Ann Surg; 2018 May; 267(5):946-951. PubMed ID: 28549010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery.
    Tadros AB; Yang WT; Krishnamurthy S; Rauch GM; Smith BD; Valero V; Black DM; Lucci A; Caudle AS; DeSnyder SM; Teshome M; Barcenas CH; Miggins M; Adrada BE; Moseley T; Hwang RF; Hunt KK; Kuerer HM
    JAMA Surg; 2017 Jul; 152(7):665-670. PubMed ID: 28423171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A qualitative study to evaluate physician attitudes regarding omission of surgery among exceptional responders to neoadjuvant systemic therapy for breast cancer (NRG-CC006).
    Gharzai LA; Szczygiel LA; Shumway DA; Bandos H; Julian TB; Mamounas EP; White J; De Los Santos JF; Basik M; Ganz PA; Jagsi R
    Breast Cancer Res Treat; 2021 Jun; 187(3):777-784. PubMed ID: 33740205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eliminating Breast Surgery for Invasive Cancer with Exceptional Response to Neoadjuvant Systemic Therapy: Prospective Multicenter Clinical Trial Planned Initial Feasibility Endpoint.
    Johnson HM; Valero V; Yang WT; Smith BD; Krishnamurthy S; Shen Y; Lin H; Lucci A; Rauch GM; Kuerer HM
    J Am Coll Surg; 2023 Jul; 237(1):101-108. PubMed ID: 36856291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy.
    Samiei S; van Nijnatten TJA; de Munck L; Keymeulen KBMI; Simons JM; Kooreman LFS; Siesling S; Lobbes MBI; Smidt ML
    Ann Surg; 2020 Mar; 271(3):574-580. PubMed ID: 30557203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omission of Breast Surgery in Predicted Pathologic Complete Response after Neoadjuvant Systemic Therapy: A Multicenter, Single-Arm, Non-inferiority Trial.
    Jung JJ; Cheun JH; Kim SY; Koh J; Ryu JM; Yoo TK; Shin HC; Ahn SG; Park S; Lim W; Nam SE; Park MH; Kim KS; Kang T; Lee J; Youn HJ; Kim YS; Yoon CI; Kim HK; Moon HG; Han W; Cho N; Kim MK; Lee HB
    J Breast Cancer; 2024 Feb; 27(1):61-71. PubMed ID: 38433091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial.
    Kuerer HM; Smith BD; Krishnamurthy S; Yang WT; Valero V; Shen Y; Lin H; Lucci A; Boughey JC; White RL; Diego EJ; Rauch GM;
    Lancet Oncol; 2022 Dec; 23(12):1517-1524. PubMed ID: 36306810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preferences Regarding Breast Surgery Omission Among Patients With Breast Cancer Who Receive Neoadjuvant Chemotherapy.
    Nakamura K; Ishitobi M; Oshiro C; Shima H; Takahashi E; Nakayama T; Shien T; Saito K; Iwatani T; Seto Y; Terata K; Kutomi G; Ogawa T; Inaji H
    In Vivo; 2023; 37(2):794-800. PubMed ID: 36881070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).
    Golshan M; Cirrincione CT; Sikov WM; Carey LA; Berry DA; Overmoyer B; Henry NL; Somlo G; Port E; Burstein HJ; Hudis C; Winer E; Ollila DW;
    Breast Cancer Res Treat; 2016 Nov; 160(2):297-304. PubMed ID: 27704226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast and axillary surgery after neoadjuvant systemic treatment - A review of clinical routine recommendations and the latest clinical research.
    Pfob A; Heil J
    Breast; 2022 Mar; 62 Suppl 1(Suppl 1):S7-S11. PubMed ID: 35135710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical Treatment After Neoadjuvant Systemic Therapy in Young Women With Breast Cancer: Results From a Prospective Cohort Study.
    Kim HJ; Dominici L; Rosenberg SM; Zheng Y; Pak LM; Poorvu PD; Ruddy KJ; Tamimi R; Schapira L; Come SE; Peppercorn J; Borges VF; Warner E; Vardeh H; Collins LC; Gaither R; King TA; Partridge AH
    Ann Surg; 2022 Jul; 276(1):173-179. PubMed ID: 33378304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonoperative Management for Invasive Breast Cancer After Neoadjuvant Systemic Therapy: Conceptual Basis and Fundamental International Feasibility Clinical Trials.
    Kuerer HM; Vrancken Peeters MTFD; Rea DW; Basik M; De Los Santos J; Heil J
    Ann Surg Oncol; 2017 Oct; 24(10):2855-2862. PubMed ID: 28766204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.